Veille Scientifique

Patrice PIENKOWSKI
Coordinateur

 Après 3 ans de bons et loyaux services, la veille scientifique va s’arrêter ; voici les derniers articles sélectionnés à votre intention.
 
Nous avons pris cette décision difficile suite au constat d’un investissement très important pour un service rendu finalement incertain, comme l’attestent les statistiques de fréquentation de la rubrique sur ce site. 
 
Je remercie tous ceux et celles qui se sont investis dans la durée pour assurer la réussite du projet, à commencer par les responsables des groupes de veille : Emmanuel Coron (Endoscopie), Roger Faroux (Cancérologie), Pauline Jouët (Gastro-entérologie et proctologie), Stéphane Nahon (MICI), Vinciane Rebours (Pancréatologoie) et Christine Silvain (Hépatologie), mais aussi et surtout, tous les veilleurs anonymes pour la grande qualité de leur travail, leur compétence et leur persévérance.
Le travail de veille bibliographique ne disparait pas complètement malgré tout, grâce aux GastroScoops dont la fréquence va augmenter avec un objectif de diffusion hebdomadaire ; il s’agit d’un travail rédactionnel différent avec une analyse d’article plus approfondie et structurée, porteur de message important.

Restez donc fidèles à ces rubriques et visitez régulièrement le site de la SNFGE toujours très riche d’enseignements et d’informations.

Très cordialement.

Dr Patrice PIENKOWSKI

 

Six groupes animés par un responsable se chargent de ce travail tous les mois :

Cancers Endoscopie

Foie/
VB/
Addicto

Gastro/
Procto/

Nutrition
MICI Pancréas
A. LIEVRE V. VALANTIN I. ROSA P. JOUET S. NAHON V. REBOURS

V. HAUTEFEUILLE
N. WILLIET
N. FARES
Y. TOUCHEFEU

A. CULETTO
Y. LEBALEUR
G. PERROD
V. VALANTIN

C. BARRAULT
P. DUKAN
N. GANNE-CARRIE
PE. RAUTOU

H. DAMON
T. HIGUERO
V. de PARADES
F. ZERBIB

V. ABITBOL
P. FAURE
M. FUMERY
D LAHARIE
P. SEKSIK

M. CAMUS-DUBOC
E. GELSI
L. de MESTIER


Nous espérons de ce nouvel outil qu’il vous aide à accéder rapidement et sélectivement aux données nouvelles de notre discipline selon vos sujets d’intérêt, qu’ils soient larges ou très spécifiques.

Revuetrier par ordre croissant Titre Date Coup de coeur Thématique
Digestive and Liver Disease Risk of cancer in small and diminutive colorectal polyps juin. 16 Cancer colorectal (CCR)
Digestive and Liver Disease Patterns of care and outcomes in oesophageal cancer nov. 18 1 ♥ Cancers autres (hors CCR et CHC)
Digestive and Liver Disease Meta-Analysis Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis Jan. 19 1 ♥ Cancers autres (hors CCR et CHC), Pancréas
World Journal of Gastrointestinal Pharmacology and Theapeutics Massive duodenal variceal bleed; complication of extra hepatic portal hypertension: Endoscopic management and literature review déc. 15 3 ♥ Endoscopie/Imagerie
Internal Medecine Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion nov. 15 3 ♥ Endoscopie/Imagerie, Œsophage/Estomac, Cancers autres
Clinical Gastroenterology and Hepatology Risk of Pancreatic Cancer in Patients With Pancreatic Cysts and Family History of Pancreatic Cancer juil. 18 3 ♥ Pancréas/Voies biliaires
Clinical Gastroenterology and Hepatology Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. avr. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis. mai. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Jan. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn's Disease. aoû. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Jan. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression juin. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn’s Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography Jan. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Sub-clinical Inflammation in the Proximal Colon. Jan. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis juil. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. avr. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission fév. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology No Association Between Consumption of Sweetened Beverages and Risk of Later-Onset Crohn's Disease or Ulcerative Colitis. Jan. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. mar. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. aoû. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Jan. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. nov. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 juin. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. Jan. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Risk of Ectopic Pregnancy in Women With Inflammatory Bowel Disease: A 22-Year NationwideCohort Study. Jan. 18 3 ♥ MICI

Pages